Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.670 +0.150 (+3.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
News headline image
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
News headline image
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert ↗
 
Via Benzinga
News headline image
CureVac, GS Partner Release Data On Influenza Vaccine Study ↗
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
News headline image
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
News headline image
Why Biopharmaceutical Player CureVac Shares Are Rising Today ↗
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. 
Via Benzinga
News headline image
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Via ACCESSWIRE
News headline image
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
News headline image
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? ↗
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
News headline image
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Via ACCESSWIRE
News headline image
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology ↗
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Earnings Scheduled For November 14, 2023 ↗
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. 
Via Benzinga
News headline image
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Via ACCESSWIRE
News headline image
Why CureVac Stock Plunged Today ↗
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
News headline image
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
News headline image
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Announces Update to the Management Team
Via ACCESSWIRE
News headline image
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Via ACCESSWIRE
News headline image
Why Shares of CureVac Jumped This Week ↗
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate. 
Via The Motley Fool
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
News headline image
Why CureVac Stock Leaped 12% Higher Today ↗
The war on cancer advances with the German company's latest clinical development. 
Via The Motley Fool
News headline image
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.